{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:05:19Z","timestamp":1793851519262,"version":"4.6.1"},"reference-count":140,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jdiacomp.2022.108389","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T01:35:08Z","timestamp":1672709708000},"page":"108389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases"],"prefix":"10.1016","volume":"37","author":[{"given":"Yehuda","family":"Handelsman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"DeFronzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Grunberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela R.","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin D.","family":"Michos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Pratley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian A.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2022.108389_bb0005","series-title":"National Health and Nutrition Examination Survey 2017\u2013March 2020 Prepandemic Data Files Development of Files and Prevalence Estimates for Selected Health Outcomes","year":"2021"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0020","series-title":"IDF Diabetes Atlas","year":"2021"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0025","series-title":"National Diabetes Statistics Report","year":"2022"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0030","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics\u20142022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2021.108101","article-title":"DCRM multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases","volume":"36","author":"Handelsman","year":"2022","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0040","series-title":"Obesity and Overweight","year":"2021"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0045","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jacc.2022.04.046","article-title":"Trends and disparities in cardiometabolic health among U.S. adults, 1999\u20132018","volume":"80","author":"O'Hearn","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0050","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMsa2032271","article-title":"Trends in diabetes treatment and control in U.S. Adults, 1999\u20132018","volume":"384","author":"Fang","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0055","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2022.05.033","article-title":"Cardiovascular disease projections in the United States based on the 2020 census estimates","volume":"80","author":"Mohebi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0060","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2337\/dci22-0014","article-title":"Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association","volume":"45","author":"Pop-Busui","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0065","series-title":"Prevalenceof Overweight, Obesity, and Severe Obesity Among Adults Aged 20 and Over:United States, 1960\u20131962 Through 2017\u20132018","author":"Fryar","year":"2020"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0070","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/nu11020338","article-title":"DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses","volume":"11","author":"Chiavaroli","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0075","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/joim.13333","article-title":"The Mediterranean diet and health: a comprehensive overview","volume":"290","author":"Guasch-Ferr\u00e9","year":"2021","journal-title":"J Intern Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0080","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/dom.13164","article-title":"Effects of an energy-restricted low-carbohydrate, high unsaturated fat\/low saturated fat diet versus a high-carbohydrate, low-fat diet in type 2 diabetes: a 2-year randomized clinical trial","volume":"20","author":"Tay","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0085","series-title":"Physical Activity Guidelines for Americans","year":"2018"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0090","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6296896","article-title":"Effectiveness of smartphone-based physical activity interventions on individuals\u2019 health outcomes: a systematic review","volume":"2021","author":"Emberson","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12966-016-0454-y","article-title":"Efficacy of interventions that use apps to improve diet, physical activity and sedentary behaviour: a systematic review","volume":"13","author":"Schoeppe","year":"2016","journal-title":"Int J Behav Nutr Phys Act"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0100","doi-asserted-by":"crossref","DOI":"10.2196\/11819","article-title":"Consumer-based wearable activity trackers increase physical activity participation: systematic review and meta-analysis","volume":"7","author":"Brickwood","year":"2019","journal-title":"JMIR Mhealth Uhealth"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0105","doi-asserted-by":"crossref","first-page":"603","DOI":"10.7326\/L19-0524","article-title":"Cardiovascular events and mortality in white coat hypertension","volume":"171","author":"Cohen","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11886-016-0780-3","article-title":"Integrating out-of-office blood pressure in the diagnosis and management of hypertension","volume":"18","author":"Cohen","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0115","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.2337\/dc22-S007","article-title":"7. Diabetes technology: standards of medical care in diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0120","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.eprac.2021.04.008","article-title":"American Association of Clinical Endocrinology Clinical Practice guideline: the use of advanced technology in the management of persons with diabetes mellitus","volume":"27","author":"Grunberger","year":"2021","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0125","series-title":"ExpertAnalysis: Why Combination Lipid-lowering Therapy Should be Considered Early inthe Treatment of Elevated LDL-C for CV Risk Reduction","author":"Varughese","year":"2022"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0130","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/MNH.0b013e32832edc99","article-title":"Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?","volume":"18","author":"Kalaitzidis","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pcd.2016.09.003","article-title":"Clinical inertia to insulin initiation and intensification in the UK: a focused literature review","volume":"11","author":"Khunti","year":"2017","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12933-015-0260-x","article-title":"Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes","volume":"14","author":"Paul","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0145","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1172\/JCI129186","article-title":"Metabolically healthy obesity: facts and fantasies","volume":"129","author":"Smith","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0155","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.2337\/dc22-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of medical care in diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0160","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0165","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/diacare.28.4.888","article-title":"Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program","volume":"28","author":"Ratner","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0170","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/oby.2008.637","article-title":"One-year weight losses in the look AHEAD study: factors associated with success","volume":"17","author":"Wadden","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0175","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/oby.20662","article-title":"Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study","volume":"22","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0180","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s00125-021-05628-8","article-title":"Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial","volume":"65","author":"Thomsen","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0185","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1053\/j.gastro.2009.01.048","article-title":"Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction","volume":"136","author":"Kirk","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0190","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archinte.166.3.285","article-title":"Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials","volume":"166","author":"Nordmann","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0195","first-page":"Cd013334","article-title":"Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk","volume":"1","author":"Naude","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0200","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4093\/dmj.2016.40.4.253","article-title":"The effect of regular exercise on insulin sensitivity in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"40","author":"Way","year":"2016","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0205","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/archinternmed.2010.380","article-title":"Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian diabetes and exercise study (IDES)","volume":"170","author":"Balducci","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0210","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pec.2018.09.021","article-title":"Facing obesity: adapting the collaborative deliberation model to deal with a complex long-term problem","volume":"102","author":"Luig","year":"2019","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0215","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0220","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1517\/14740338.2013.806481","article-title":"Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management","volume":"12","author":"Garvey","year":"2013","journal-title":"Exp Opin Drug Safety"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0225","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0230","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0235","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD","volume":"107","author":"Patel Chavez","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0240","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/oby.23521","article-title":"Glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor poly-agonists: a new era in obesity pharmacotherapy","volume":"30","author":"Malik","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0245","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0140-6736(22)01280-6","article-title":"Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial","volume":"400","author":"Abu Dayyeh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0250","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(21)02394-1","article-title":"Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial","volume":"398","author":"Abu Dayyeh","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0255","doi-asserted-by":"crossref","first-page":"O1","DOI":"10.1002\/oby.22719","volume":"28","author":"Mechanick","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0260","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052036","article-title":"Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis","volume":"7","author":"Gast","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0270","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1210\/jc.2007-0334","article-title":"Insulin resistance, insulin response, and obesity as indicators of metabolic risk","volume":"92","author":"Ferrannini","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0275","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.CIR.102.1.42","article-title":"Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS)","volume":"102","author":"Festa","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0280","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.2174\/1381612822666160720155855","article-title":"Insulin resistance and polycystic ovary syndrome","volume":"22","author":"Moghetti","year":"2016","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0285","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2020.01.046","article-title":"Uric acid and estimate of renal function. Let's stick together","volume":"310","author":"Borghi","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0290","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0295","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0300","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0305","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0310","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.3390\/ijms23084110","article-title":"Controversies in the pathogenesis, diagnosis and treatment of PCOS: focus on insulin resistance, inflammation, and hyperandrogenism","volume":"23","author":"Armanini","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0315","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0320","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0325","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0330","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/CS-2019-0472","article-title":"Consensus statement by the american Association of Clinical Endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm\u20142020 executive summary","volume":"26","author":"Garber","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0335","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.2337\/dc22-S011","article-title":"11. Chronic kidney disease and risk management: standards of medical care in diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0340","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.2337\/dc22-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0345","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1016\/j.jacc.2021.03.335","article-title":"Glycated hemoglobin and subclinical atherosclerosis in people without diabetes","volume":"77","author":"Rossello","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0350","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.2337\/dc22-S003","article-title":"3. Prevention or delay of type 2 diabetes and associated comorbidities: standards of medical care in diabetes\u20142022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0355","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1464-5491.2007.02043.x","article-title":"The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the diabetes prevention program","volume":"24","year":"2007","journal-title":"Diabet Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0360","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1038\/s41467-020-18386-9","article-title":"An investigation of causal relationships between prediabetes and vascular complications","volume":"11","author":"Mutie","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0365","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/1535370220915644","article-title":"Regression from prediabetes to normal glucose regulation: state of the science","volume":"245","author":"Sallar","year":"2020","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0370","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/db10-1392","article-title":"Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT","volume":"60","author":"Kahn","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0375","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2337\/dc15-2251","article-title":"Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis","volume":"39","author":"Guasch-Ferr\u00e9","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP15672.GLSUPPL","article-title":"American Association of Clinical Endocrinologists and American College of endocrinology: clinical practice guidelines for developing a diabetes mellitus comprehensive care plan\u20142015","volume":"21","author":"Handelsman","year":"2015","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0385","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4158\/EP.14.7.933","article-title":"Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists","volume":"14","author":"Garber","year":"2008","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0390","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jand.2015.02.031","article-title":"Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"115","author":"Franz","year":"2015","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0395","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0400","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2174\/1573399816666191230113446","article-title":"Liraglutide therapy in a prediabetic state: rethinking the evidence","volume":"16","author":"Papaetis","year":"2020","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0405","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0410","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0415","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0420","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2337\/dc20-2439","article-title":"Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88","volume":"44","author":"Lind","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0425","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.2337\/dc20-3097","article-title":"Understanding metabolic memory: the prolonged influence of glycemia during the Diabetes Control and Complications Trial (DCCT) on future risks of complications during the study of the Epidemiology of Diabetes Interventions and Complications (EDIC)","volume":"44","author":"Lachin","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0430","doi-asserted-by":"crossref","DOI":"10.2337\/dci21-0030","article-title":"Lingering effects of hyperglycemia in recently diagnosed diabetes during long-term follow-up of the DCCT\/EDIC and UKPDS cohorts: more evidence that early control matters","author":"Riddle","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0435","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.2337\/dc21-1331","article-title":"The beneficial effects of earlier versus later implementation of intensive therapy in type 1 diabetes","volume":"44","author":"Lachin","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0440","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.amepre.2019.02.005","article-title":"Team-based care to improve diabetes management: a community guide meta-analysis","volume":"57","author":"Levengood","year":"2019","journal-title":"Am J Prevent Med."},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0445","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.2337\/dci20-0017","article-title":"Cost-effectiveness of interventions to manage diabetes: has the evidence changed since 2008?","volume":"43","author":"Siegel","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0450","series-title":"National Diabetes Statistics Report, 2017","year":"2017"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2017.11.005","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Card."},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0460","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 2018 ESC\/ESH guidelines for the management of arterial hypertension: the task force for the Management of Arterial Hypertension of the european Society of Cardiology (ESC) and the european Society of Hypertension (ESH)","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0465","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study","volume":"123","author":"Peterson","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0470","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M20-4298","article-title":"Effects of intensive blood pressure treatment on orthostatic hypotension: a systematic review and individual participant-based meta-analysis","volume":"174","author":"Juraschek","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0475","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1097\/HJH.0000000000002088","article-title":"Redefining diuretics use in hypertension: why select a thiazide-like diuretic?","volume":"37","author":"Burnier","year":"2019","journal-title":"J Hypertens"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0480","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0490","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0495","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCULATIONAHA.122.059410","volume":"146","author":"Ridker","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0500","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0505","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0510","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0515","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0520","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology (Baltimore, Md)."},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0525","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2337\/dc16-1787","article-title":"Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action","volume":"40","author":"Bril","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0530","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0535","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0540","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jcmg.2020.12.024","article-title":"Coronary artery calcium for the allocation of glp-1ra for primary prevention of atherosclerotic cardiovascular disease","volume":"14","author":"Cainzos-Achirica","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0545","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1161\/CIRCULATIONAHA.119.045010","article-title":"Coronary artery calcium for personalized allocation of aspirin in primary prevention of cardiovascular disease in 2019: the MESA study (Multi-ethnic study of Atherosclerosis)","volume":"141","author":"Cainzos-Achirica","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0550","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jacl.2020.12.005","article-title":"The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction","volume":"15","author":"Orringer","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0555","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the american College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0560","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.atherosclerosis.2022.02.006","article-title":"Coronary artery calcium scores indicating secondary prevention level risk: findings from the CAC consortium and FOURIER trial","volume":"347","author":"Dzaye","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0565","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0570","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"Improving global outcomes (KDIGO) diabetes work group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"Disease","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0575","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0580","first-page":"337","article-title":"KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0585","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0590","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0595","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0600","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0605","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0610","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2215\/CJN.18881220","article-title":"SGLT2 inhibitors in diabetic kidney disease","volume":"16","author":"Zoungas","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0615","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0620","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0625","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0630","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/VHRM.S83662","article-title":"Targeting heart failure with preserved ejection fraction: current status and future prospects","volume":"12","author":"Kanwar","year":"2016","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0635","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12471-016-0811-0","article-title":"How to diagnose heart failure with preserved ejection fraction: the value of invasive stress testing","volume":"24","author":"Huis In't Veld","year":"2016","journal-title":"Neth Heart J"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcmg.2017.08.007","article-title":"Epidemiology of left ventricular systolic dysfunction and heart failure in the Framingham study: an echocardiographic study over 3 decades","volume":"11","author":"Vasan","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0645","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0650","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCULATIONAHA.119.042685","article-title":"Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus","volume":"140","author":"Berg","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0655","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.2337\/dc19-0587","article-title":"Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes: the WATCH-DM risk score","volume":"42","author":"Segar","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0660","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jchf.2020.10.013","article-title":"Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes","volume":"9","author":"Pandey","year":"2021","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0665","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1161\/CIRCULATIONAHA.116.025505","article-title":"High-sensitive cardiac troponin T as an early biochemical signature for clinical and subclinical heart failure: MESA (Multi-ethnic study of Atherosclerosis)","volume":"135","author":"Seliger","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0670","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0675","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ejhf.2397","article-title":"Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction","volume":"24","author":"Tomasoni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0680","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ejhf.2420","article-title":"Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-preserved trial","volume":"24","author":"Butler","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0685","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0690","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2022.02.010","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"28","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0695","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2022.108389_bb0700","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872722003014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872722003014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:17:10Z","timestamp":1761005830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872722003014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":140,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1056872722003014"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108389","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108389","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"108389"}}